Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
V930 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | V930 |
| 2 | EXPERIMENTAL | V932 |
| Name | Type | Description |
|---|---|---|
| V930 | BIOLOGICAL | V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses. |
| V932 | BIOLOGICAL | V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection). |
Inclusion Criteria: * Patients must have completed surgical treatment for his/her primary disease at least 1 month prior to enrollment * Patient must not be pregnant 3 days prior to enrollment Exclusion Criteria: * Patient is currently participating or has participated in a study with an investig...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
V930 is an investigational monoclonal antibody being studied for the treatment of cancers expressing HER-2 and/or carcinoembryonic antigen (CEA). It has been evaluated in Phase 1 clinical trials in patients with these cancers, as well as in healthy volunteers for tolerability studies.
V930 targets cancers that express HER-2 and/or carcinoembryonic antigen (CEA). As a monoclonal antibody, it is designed to interact with these cancer-associated markers, though the specific molecular mechanism of action has not been detailed in the available information.
V930 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company has sponsored Phase 1 clinical trials to evaluate the drug's safety and tolerability.
V930 is in Phase 1 clinical development. All three clinical trials listed for V930 are Phase 1 studies and have been completed. The drug remains investigational and has not been approved by regulatory authorities for commercial use.
V930 has been studied in three completed Phase 1 trials: NCT00250419, a first-in-human study in patients with cancers expressing HER-2 and/or CEA; NCT00647114, a study of V930/V932 in patients with HER-2 and/or CEA-expressing cancers; and NCT00721461, a tolerability study in healthy adults.
V930 and V932 are distinct investigational agents that have been studied together in a clinical trial. The study NCT00647114 evaluated both V930 and V932 in patients with cancers expressing HER-2 and/or CEA, but they are not described as the same drug.